undamentalytics Newsletter

Hedge fund

RA Capital Management, L.P.

13F for the quarter to June 30, 2026, filed August 14, 2026 · SEC CIK 1346824

Reported value
$11.5bn
96% in companies we cover
Positions we cover
76
Largest ASND 23.8%
Copy, a year
−1.7%
S&P 500 +14.1%
Copy Sharpe ratio
0.13
S&P 500 0.78

How copying its 13F would have done

$5.0k$10.0k$20.0k$40.0k 2013201520172019202120232025 $57.0k$7.9k
CopyS&P 500 $10,000 copying RA Capital Management, L.P.'s filed holdings in companies we cover from August 16, 2013, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −80.2% (S&P 500 −31.8%); beta 1.10; alpha −8.4% a year (t = −0.79); last 12 months +1.4% against +12.1%.

Reported value by quarter

RA Capital Management, L.P.: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $2T $4T $6T Reported value, 2013-06-30: $615.8M Reported value, 2013-09-30: $724.3M Reported value, 2013-12-31: $647.8M Reported value, 2014-03-31: $973.5M Reported value, 2014-06-30: $756.1M Reported value, 2014-09-30: $621.6M Reported value, 2014-12-31: $776.5M Reported value, 2015-03-31: $912.9M Reported value, 2015-06-30: $927.6M Reported value, 2015-09-30: $696.3M Reported value, 2015-12-31: $1B Reported value, 2016-03-31: $782.3M Reported value, 2016-06-30: $722.2M Reported value, 2016-09-30: $969.4M Reported value, 2016-12-31: $705.8M Reported value, 2017-03-31: $815.3M Reported value, 2017-06-30: $871.4M Reported value, 2017-09-30: $1.1B Reported value, 2017-12-31: $1.2B Reported value, 2018-03-31: $1.3B Reported value, 2018-06-30: $1.5B Reported value, 2018-09-30: $1.9B Reported value, 2018-12-31: $1.7B Reported value, 2019-03-31: $2.3B Reported value, 2019-06-30: $1.9B Reported value, 2019-09-30: $1.7B Reported value, 2019-12-31: $3.3B Reported value, 2020-03-31: $3.2B Reported value, 2020-06-30: $5.1B Reported value, 2020-09-30: $5.5B Reported value, 2020-12-31: $7.2B Reported value, 2021-03-31: $6.6B Reported value, 2021-06-30: $6.2B Reported value, 2021-09-30: $7.2B Reported value, 2021-12-31: $5.7B Reported value, 2022-03-31: $4.6B Reported value, 2022-06-30: $3.8B Reported value, 2022-09-30: $4.7B Reported value, 2022-12-31: $4.9T Reported value, 2023-03-31: $4.4B Reported value, 2023-06-30: $5.3B Reported value, 2023-09-30: $5.1B Reported value, 2023-12-31: $6.4B Reported value, 2024-03-31: $7.9B Reported value, 2024-06-30: $7.6B Reported value, 2024-09-30: $8.7B Reported value, 2024-12-31: $7.5B Reported value, 2025-03-31: $6B Reported value, 2025-06-30: $5.9B Reported value, 2025-09-30: $8.1B Reported value, 2025-12-31: $9.8B Reported value, 2026-03-31: $9.4B Reported value, 2026-06-30: $11.5B 2013-06-30 2016-03-31 2018-12-31 2021-09-30 2026-06-30 $11.5B
View chart data
Period Reported value
2013-06-30 $615.8M
2013-09-30 $724.3M
2013-12-31 $647.8M
2014-03-31 $973.5M
2014-06-30 $756.1M
2014-09-30 $621.6M
2014-12-31 $776.5M
2015-03-31 $912.9M
2015-06-30 $927.6M
2015-09-30 $696.3M
2015-12-31 $1B
2016-03-31 $782.3M
2016-06-30 $722.2M
2016-09-30 $969.4M
2016-12-31 $705.8M
2017-03-31 $815.3M
2017-06-30 $871.4M
2017-09-30 $1.1B
2017-12-31 $1.2B
2018-03-31 $1.3B
2018-06-30 $1.5B
2018-09-30 $1.9B
2018-12-31 $1.7B
2019-03-31 $2.3B
2019-06-30 $1.9B
2019-09-30 $1.7B
2019-12-31 $3.3B
2020-03-31 $3.2B
2020-06-30 $5.1B
2020-09-30 $5.5B
2020-12-31 $7.2B
2021-03-31 $6.6B
2021-06-30 $6.2B
2021-09-30 $7.2B
2021-12-31 $5.7B
2022-03-31 $4.6B
2022-06-30 $3.8B
2022-09-30 $4.7B
2022-12-31 $4.9T
2023-03-31 $4.4B
2023-06-30 $5.3B
2023-09-30 $5.1B
2023-12-31 $6.4B
2024-03-31 $7.9B
2024-06-30 $7.6B
2024-09-30 $8.7B
2024-12-31 $7.5B
2025-03-31 $6B
2025-06-30 $5.9B
2025-09-30 $8.1B
2025-12-31 $9.8B
2026-03-31 $9.4B
2026-06-30 $11.5B

Holdings and moves

CompanyShare of portfolioValueSharesChange in shares
ASNDAscendis Pharma A/s23.83%$2.7bn10.28MNew
PBLSParabilis Medicines, Inc.6.88%$791.9m28.93MNew
RYTMRhythm Pharmaceuticals, Inc.6.43%$740.2m6.67M0.0%
PCVXVaxcyte, Inc.5.80%$667.0m11.47M0.0%
SIONSionna Therapeutics, Inc.3.79%$435.7m9.91M0.0%
TYRATyra Biosciences, Inc.3.39%$389.6m12.20M0.0%
EWTXEdgewise Therapeutics, Inc.2.96%$341.0m8.39M−19.5% Reduced
NAMSNewamsterdam Pharma Co N.V.2.81%$323.7m9.55M0.0%
COAGHemab Therapeutics Holdings, Inc.2.49%$286.8m7.81MNew
SEPNSepterna, Inc.2.04%$234.3m7.00M0.0%
BCAXBicara Therapeutics Inc.1.87%$215.4m7.26M0.0%
MLYSMineralys Therapeutics, Inc.1.80%$207.6m7.69M0.0%
GHRSGH Research PLC1.78%$205.3m7.64M−0.5% Reduced
IRONDisc Medicine, Inc.1.56%$179.2m2.45M0.0%
SGPSpyglass Pharma, Inc.1.55%$178.6m8.02M0.0%
ARTVArtiva Biotherapeutics, Inc.1.51%$174.2m17.96M+82.2% Added
JANXJanux Therapeutics, Inc.1.49%$171.9m11.19M0.0%
TSHATaysha Gene Therapies, Inc.1.39%$160.4m23.56M0.0%
BCRXBiocryst Pharmaceuticals Inc1.38%$158.3m15.83M0.0%
ABVXAbivax S.a.1.31%$150.9m1.13MNew
ORKAOruka Therapeutics, Inc.1.29%$148.0m1.55MNew
CLYMClimb Bio, Inc.1.28%$147.4m11.30M0.0%
SLDBSolid Biosciences Inc.1.04%$120.2m12.04M+28.9% Added
ZLABZai Lab Ltd0.95%$109.1m5.74M+0.6% Added
SPRYARS Pharmaceuticals, Inc.0.76%$87.0m10.86M0.0%
XNCRXencor Inc0.74%$84.9m5.27M+7.7% Added
JBIOJade Biosciences, Inc.0.71%$81.6m3.67M0.0%
NTLAIntellia Therapeutics, Inc.0.67%$76.6m4.53MNew
LBRXLB Pharmaceuticals Inc0.62%$71.7m2.21M0.0%
DFTXDefinium Therapeutics, Inc.0.61%$70.6m1.50MNew
ACRSAclaris Therapeutics, Inc.0.58%$67.3m12.72M+87.0% Added
FDMT4d Molecular Therapeutics, Inc.0.58%$67.2m5.05M0.0%
SANASana Biotechnology, Inc.0.57%$65.4m18.75MNew
MNPRMonopar Therapeutics0.54%$61.8m667.2K0.0%
ABOSAcumen Pharmaceuticals, Inc.0.49%$56.1m20.99M0.0%
GERNGeron Corp0.48%$54.8m42.81M−32.9% Reduced
RZLTRezolute, Inc.0.43%$49.1m9.45M+2.9% Added
EVMNEvommune, Inc.0.40%$46.4m3.49M0.0%
VORVor Biopharma Inc.0.38%$44.2m2.40M−55.6% Reduced
IPSCCentury Therapeutics, Inc.0.38%$43.5m17.75M0.0%
AKTSAktis Oncology, Inc.0.37%$42.4m1.31M−12.6% Reduced
BIOABioage Labs, Inc.0.36%$41.0m1.67M+1.3% Added
CCCCC4 Therapeutics, Inc.0.33%$37.4m8.00M0.0%
MIRMMirum Pharmaceuticals, Inc.0.32%$37.3m318.6K0.0%
CAPRCapricor Therapeutics, Inc.0.32%$36.3m1.51M0.0%
PEPGPepgen Inc.0.31%$36.1m20.06M0.0%
PRLDPrelude Therapeutics Inc0.30%$34.5m6.48MNew
NKTXNkarta, Inc.0.27%$30.6m10.81M0.0%
QTTBQ32 Bio Inc.0.26%$29.7m2.33MNew
AVRAnteris Technologies Global Corp.0.26%$29.6m3.00M0.0%
EDITEditas Medicine, Inc.0.25%$28.8m8.89MNew
OVIDOvid Therapeutics Inc.0.24%$28.2m10.50M−2.0% Reduced
ASMBAssembly Biosciences, Inc.0.24%$28.0m1.02M0.0%
ALXOALX Oncology Holdings Inc0.23%$26.9m13.01M0.0%
BNTCBenitec Biopharma Inc.0.21%$24.8m1.85M0.0%
LENZLenz Therapeutics, Inc.0.21%$23.7m4.18M0.0%
LXEOLexeo Therapeutics, Inc.0.20%$23.3m5.00M0.0%
ACRVAcrivon Therapeutics, Inc.0.19%$21.8m12.23M+46.6% Added
ALTAltimmune, Inc.0.17%$19.8m6.50MNew
KPTIKaryopharm Therapeutics Inc.0.16%$18.7m1.92M0.0%
DRUGBright Minds Biosciences Inc.0.16%$18.6m265.0K0.0%
AVTXAvalo Therapeutics, Inc.0.16%$18.5m1.00M+50.8% Added
OKUROnkure Therapeutics, Inc.0.16%$18.2m4.00M0.0%
FTHFaeth Therapeutics, Inc.0.16%$18.1m722.0KNew
AURAAura Biosciences, Inc.0.15%$17.8m2.50MNew
SABSSAB Biotherapeutics, Inc.0.15%$17.2m4.40M0.0%
SPTXSeaport Therapeutics, Inc.0.13%$15.2m700.0KNew
PALIPalisade BIO, Inc.0.13%$14.9m7.12M0.0%
WAYWaystar Holding Corp.0.09%$10.9m529.4K0.0%
EQEquillium, Inc.0.09%$9.9m3.10M0.0%
MGNXMacrogenics Inc0.07%$8.6m1.86M0.0%
ACETAdicet Bio, Inc.0.07%$8.1m932.6K−21.1% Reduced
CRVSCorvus Pharmaceuticals, Inc.0.06%$6.7m450.0K0.0%
RANIRani Therapeutics Holdings, Inc.0.06%$6.5m8.50M0.0%
HOWLWerewolf Therapeutics, Inc.0.01%$859,3492.39M−64.3% Reduced
PTNPalatin Technologies Inc0.01%$670,31862.1K−11.3% Reduced
CompanyBought (value)Shares
ASNDAscendis Pharma A/s$2.7bn10.28M
PBLSParabilis Medicines, Inc.$791.9m28.93M
COAGHemab Therapeutics Holdings, Inc.$286.8m7.81M
ABVXAbivax S.a.$150.9m1.13M
ORKAOruka Therapeutics, Inc.$148.0m1.55M
ARTVArtiva Biotherapeutics, Inc.$78.6m8.10M
NTLAIntellia Therapeutics, Inc.$76.6m4.53M
DFTXDefinium Therapeutics, Inc.$70.6m1.50M
SANASana Biotechnology, Inc.$65.4m18.75M
PRLDPrelude Therapeutics Inc$34.5m6.48M
ACRSAclaris Therapeutics, Inc.$31.3m5.92M
QTTBQ32 Bio Inc.$29.7m2.33M
EDITEditas Medicine, Inc.$28.8m8.89M
SLDBSolid Biosciences Inc.$26.9m2.70M
ALTAltimmune, Inc.$19.8m6.50M

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
DNTHDianthus Therapeutics, Inc.−$219.2m−2.61M
PRAXPraxis Precision Medicines, Inc.−$120.4m−373.8K
SRPTSarepta Therapeutics, Inc.−$84.9m−3.90M
EWTXEdgewise Therapeutics, Inc.−$82.7m−2.04M
SYRESpyre Therapeutics, Inc.−$81.8m−1.62M
VORVor Biopharma Inc.−$55.3m−3.00M
FULCFulcrum Therapeutics, Inc.−$46.4m−6.05M
OLMAOlema Pharmaceuticals, Inc.−$38.8m−2.60M
DSGNDesign Therapeutics, Inc.−$31.6m−2.97M
GERNGeron Corp−$26.8m−20.96M
TVTXTravere Therapeutics, Inc.−$22.2m−746.8K
GRALGrail, Inc.−$22.1m−428.3K
RLMDRelmada Therapeutics, Inc.−$20.5m−2.95M
STROSutro Biopharma, Inc.−$17.8m−715.3K
CTNMContineum Therapeutics, Inc.−$16.9m−1.30M

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
DNTHDianthus Therapeutics, Inc.$219.2m2.61M
PRAXPraxis Precision Medicines, Inc.$120.4m373.8K
SRPTSarepta Therapeutics, Inc.$84.9m3.90M
SYRESpyre Therapeutics, Inc.$81.8m1.62M
FULCFulcrum Therapeutics, Inc.$46.4m6.05M
OLMAOlema Pharmaceuticals, Inc.$38.8m2.60M
DSGNDesign Therapeutics, Inc.$31.6m2.97M
TVTXTravere Therapeutics, Inc.$22.2m746.8K
GRALGrail, Inc.$22.1m428.3K
RLMDRelmada Therapeutics, Inc.$20.5m2.95M
STROSutro Biopharma, Inc.$17.8m715.3K
CTNMContineum Therapeutics, Inc.$16.9m1.30M
INSPInspire Medical Systems, Inc.$16.8m325.7K
HNGEHinge Health, Inc.$14.1m364.6K
WGSGenedx Holdings Corp.$13.5m209.9K
RNAAtrium Therapeutics, Inc.$11.6m864.1K
MPLTMaplight Therapeutics, Inc.$5.0m248.3K
  • Health Care100.0%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestAugust 16, 2013 to November 2, 2026−1.7%+14.1%0.130.78−80.2%1.10
2018 onwardsJanuary 5, 2018 to November 2, 2026−6.0%+13.9%−0.010.66−78.2%1.04
Last three yearsNovember 3, 2023 to November 2, 2026+13.2%+21.8%0.401.16−54.3%1.41
Last yearNovember 7, 2025 to November 2, 2026+11.4%+14.2%0.370.84−25.4%1.22

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.